Explore ARTISTRY-1 Trial Results
In the News
Journal for ImmunoTherapy of Cancer (JITC) Publication
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Press Release
Mural Highlights Promising ARTISTRY-1 Trial Results in JITC
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Watch Now
Nemvaleukin | Clinical Results from the ARTISTRY-1 Trial
Dr. Ulka Vaishampayan, Professor of Internal Medicine in the Division of Hematology/Oncology at the University of Michigan, provides an in-depth overview of the promising results from the ARTISTRY-1 phase 1/2 clinical trial of nemvaleukin alfa (nemvaleukin).
